A Randomized, Double-blind Comparative Study Comparing Ferric Carboxymaltose (Ferinject) and Iron Isomaltoside 1000 (Monofer) for Iron Substitution in Iron-deficiency Anemia
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Incidence of hypophosphatemia
研究概览
简要总结
The purpose of this study is to determine to what extend a treatment with the iron compounds Iron Isomaltoside 1000 or Ferric Carboxymaltose is leading to hypophosphatemia and to study the potential clinical impact of hypophosphatemia.
详细描述
Recent studies suggested that intravenous iron preparations for anemia treatment may have adverse effects on phosphorus regulation, as they may induce an increase in the phosphaturic hormone Fibroblast Growth Factor-23 (FGF-23) and a subsequent fall in plasma phosphorus levels.
So far it is unknown if these effects are class- or substance-specific.
This study will address the question whether among female participants with iron deficiency anemia the application of ferric-(III)-derisomaltose and ferric carboxymaltose will cause episodes of hypophosphatemia to same extend. The investigators will additionally compare the effects of the two iron preparations on other parameters of calcium-phosphate metabolism, and decipher potential consequences of hypophosphatemia by analysing cardiac function, immunological parameters and quality of life.
In order to investigate these outcomes, 60 women with iron deficient anemia will be randomised to receive either ferric-(III)-derisomaltose or ferric carboxymaltose.
The monocentric study will be conducted at Saarland University Medical Center. For each participating woman, the study comprises five visits to the study center during a period of five weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •written informed consent,
- •gynecological blood losses,
- •age ≥ 18 years,
- •iron deficiency anemia,
- •Hemoglobin < 12,0 g/dl,
- •Serum-Ferritin ≤ 100 ng/ml or Serum-Ferritin ≤ 300 ng/ml and Transferrin-saturation ≤ 30 %,
- •Intolerance to or inefficacy of an oral iron supplement
- •estimated Glomerular Filtration Rate > 15 ml/min/1.73 m²
排除标准
- •known hypersensitivity to MonoFer® or FERINJECT®,
- •severe, known hypersensitivity to other intravenous iron preparations,
- •Plasma Phosphate < 2.5 mg/dl at screening,
- •Hemochromatosis,
- •Untreated hyperparathyroidism,
- •Renal replacement therapy/kidney transplantation,
- •Active malignant disease, disease-free survival for less than 5 years,
- •Intravenous iron administration within the last 30 days,
- •Treatment with erythropoietin or erythropoietin-stimulating agents, transfusion of red blood cells, radiotherapy or chemotherapy within the last 60 days,
- •Surgery under anesthetic within the last 10 days,
- •Alanine transaminase (ALT) or aspartate transaminase (AST) > 1.5 fold above levels in healthy individuals,
- •Acute febrile infections within the last 7 days,
- •Chronic inflammatory diseases requiring a systemic antiinflammatory treatment,
- •self-reported severe asthma or eczema,
- •presence of relative contraindications (any allergy, any immunologic or inflammatory disease, history of atopic allergies), for which a treatment with the medicinal investigational products is not deemed indicated by the investigator,
- •pregnancy,
- •women of childbearing potential without an effective method of contraception,
- •lactating women,
- •Present alcohol or drug dependency,
- •Patients with a history of a psychological illness or seizures,
- •Non-compliance or administration of any investigational drug within 30 days preceding the study start.
研究组 & 干预措施
Iron Isomaltoside 1000
Subjects receive Iron Isomaltoside 1000 solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
干预措施: Iron Isomaltoside 1000 (Drug)
Ferric Carboxymaltose
Subjects receive Ferric Carboxymaltose solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
干预措施: Ferric Carboxymaltose (Drug)
结局指标
主要结局
Incidence of hypophosphatemia
时间窗: From baseline to day 35
The incidence of hypophosphatemia is defined as a drop of serum phosphate below 2.0 mg/dl.
次要结局
- Changes of fractional Phosphate urinary excretion.(From baseline to day 35)
- Changes of Plasma Hepcidin-25.(From baseline to day 35)
- Changes of Plasma Vitamin D (active, inactive).(From baseline to day 35)
- Changes of fibroblast growth factor 23 (intact and c-terminal).(From baseline to day 35)
- Changes of plasma phosphate concentrations.(From baseline to day 35)
- Changes of parathyroid Hormone.(From baseline to day 35)
- Changes of Plasma calcium.(From baseline to day 35)
- Changes of Plasma alkaline Phosphatase.(From baseline to day 35)
- Changes of Plasma soluble Klotho.(From baseline to day 35)
- Changes of Serum N-Terminal Propeptide of Type I Collagen (PINP).(From baseline to day 35)
- Changes of Pyridinoline (PYD) in the urine(From baseline to day 35)
- Changes of Quality of life.(From baseline to day 35)
- Incidence of (supra)ventricular cardiac arrhythmias in the ambulatory Electrocardiography.(Before and 7 days after administration of iron compound)
- Changes of QT-time in the 12-lead Electrocardiography.(From baseline to day 35)
- Changes of QT-Dispersion in the 12-lead Electrocardiography.(From baseline to day 35)
- Changes of Left Ventricular Mass Index(From baseline to day 7)
- Count of monocyte subpopulations.(Right before the singular infusion of the iron compound is started and right after infusion of the iron compound is completed.)
- Measurement of phagocytic capacity of monocytes.(Right before the singular infusion of the iron compound is started and right after the infusion of iron compound is completed.)
- Changes of fatigue(From baseline to day 35)
- Changes of Left Atrial Volume Index(From Baseline to day 7)
- Changes of Systolic Ejection Fraction(From Baseline to day 7)
- Changes of Diastolic Left Ventricular Function(From Baseline to day 7)